A rapidly growing understanding of the complex circuitry of microRNA (miRNA)-mediated gene regulation is attracting attention to miRNAs as new drug targets. Targeted miRNA suppression is achieved in a sequence-specific […]
All posts by signagen - 32. page
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
On July 1, 2014, the United States Food and Drug Administration granted ‘breakthrough therapy’ designation to CTL019, the anti-CD19 chimeric antigen receptor T-cell therapy developed at the University of Pennsylvania. […]
The CAR T-Cell Race
Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way. By Vicki Brower | April 1, 2015 BUILDING A BETTER T-CELL: […]
First Success With CAR T-Cells in a Solid Tumor
Chimeric antigen-receptor (CAR) T-cell therapy has repeatedly provided dramatic results in patients with hematologic malignancies. Now comes the first success story of CAR T-cell therapy in a solid tumor — […]
CAR T-CELL BIOTECH IPOs
Company Date Value Kite Pharma June 2014 $134.1 million Bellicum December 2014 $160 million Juno December 2014 $264.6 million Cellectis March 2015 $228 million
CAR T-CELL DEALS
Institution/Company Date Partner Terms University of Pennsylvania August 2012 Novartis Undisclosed Celgene March 2013 Bluebird Bio, Baylor College of Medicine Unspecified upfront payment plus up to $225 million per product […]
AAV9 VRs and their reported functional roles
AAV9 VRs and their reported functional roles. Refer to http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393551 VR AAV9 aa Reported functional role(s) References VR-I 262–269 Unknown in AAV9 VR-II 327–332 DE loop at the 5-fold channel; […]
Nucleotide and amino acid identities between rodent and other AAV capsids
AAV-mo.1 AAV-ra.1 AAV-1 AAV-2 AAV-hu.2 AAV-3a AAV-4 AAV-5 AAV-7 AAV-8 AAV-9 Avian Snake % Amino acid identity AAV-mo.1 100 58 56 56 56 55 51 53 56 56 56 […]
AAV5 Capsid Protein VP1
10 20 30 40 50 MSFVDHPPDW LEEVGEGLRE FLGLEAGPPK PKPNQQHQDQ ARGLVLPGYN 60 70 80 90 100 YLGPGNGLDR GEPVNRADEV AREHDISYNE QLEAGDNPYL KYNHADAEFQ 110 120 130 140 150 EKLADDTSFG GNLGKAVFQA KKRVLEPFGL VEEGAKTAPT GKRIDDHFPK […]
AAV10 Capsid Protein VP1
10 20 30 40 50 MAADGYLPDW LEDNLSEGIR EWWDLKPGAP KPKANQQKQD DGRGLVLPGY 60 70 80 90 100 KYLGPFNGLD KGEPVNAADA AALEHDKAYD QQLKAGDNPY LRYNHADAEF 110 120 130 140 150 QERLQEDTSF GGNLGRAVFQ AKKRVLEPLG LVEEAAKTAP GKKRPVEPSP […]